Finding potential biomarkers to predict response to immunotherapy in nonhypermutated cancers

Scientists have discovered a potential biomarker that could more accurately identify which patients with non-hypermutated cancers will respond to specialized immunotherapy drugs called immune checkpoint inhibitors, according to findings published in Science Translational Medicine.